Tag: Cardiol Therapeutics Inc.
August 26, 2020
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)
Study Designed to Support Cardiol Therapeutics' Phase 2 International Trial in Acute Myocarditis
May 14, 2020
Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering
Cardiol Therapeutics has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. to increase the...
May 13, 2020
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) has entered into an agreement with Canaccord Genuity.
May 6, 2020
Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
Cardiol Therapeutics is pleased to announce the filing of a new patent application covering the use of cannabidiol (CBD) to...
April 14, 2020
Cardiol Announces Study Demonstrating Its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart
Results showed a greater than 100-fold increase in uptake of Cardiol's nanoparticles in heart failure hearts compared with control hearts
April 1, 2020
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
Data Accepted for Presentation at the American College of Cardiology Annual Meeting
March 27, 2020